AKCA Shares Outstanding History
Below is a table of the AKCA shares outstanding history going back to 7/14/2017:

Date AKCA Shares Outstanding
7/14/201750.59M
8/2/201766.54M
11/1/201766.54M
2/20/201866.63M
4/30/201885.59M
7/31/201885.72M
10/31/201889.21M
2/20/201989.43M
5/2/201992.77M
8/1/201993.03M
8/5/2019148.38M
10/31/201993.90M
2/20/2020101.07M
4/29/2020101.51M
7/29/2020101.60M

Also see: AKCA Market Cap History
AKCA YTD Return
AKCA Historical Shares Outstanding:
+25.74% CAGR
AKCA Historical Shares Outstanding: +25.74% CAGR

Mouse over chart for data details
7/14/2017 ...7/29/2020
Akcea Therapeutics is a commercial stage biopharmaceutical company developing and commercializing medicines to treat patients. Co. is focused on commercializing its approved therapies, TEGSEDI and WAYLIVRA. TEGSEDI is indicated to treat adults with the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and has been approved and launched in the United States, the European Union, and Canada as well as approved in Brazil. WAYLIVRA is indicated as an adjunct to diet to treat adult patients with genetically confirmed familial chylomicronemia syndrome, who are at high risk for pancreatitis, for whom response to diet and triglyceride lowering therapy has been inadequate. We show 15 historical shares outstanding datapoints in our coverage of AKCA's shares outstanding history.

Understanding the changing numbers of AKCA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AKCA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AKCA by allowing them to research AKCA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for AKCA:
AKCA SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Akcea Therapeutics (AKCA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AKER Shares Outstanding History
AKRX Shares Outstanding History
ALBO Shares Outstanding History
ALC Shares Outstanding History
ALDR Shares Outstanding History
ALDX Shares Outstanding History
ALGN Shares Outstanding History
ALIM Shares Outstanding History
ALKS Shares Outstanding History
ALNA Shares Outstanding History
More Healthcare companies »

 

AKCA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.